1. Home
  2. PGEN vs DEI Comparison

PGEN vs DEI Comparison

Compare PGEN & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.96

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$10.24

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
DEI
Founded
1998
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
PGEN
DEI
Price
$3.96
$10.24
Analyst Decision
Buy
Hold
Analyst Count
5
8
Target Price
$8.33
$12.94
AVG Volume (30 Days)
5.6M
2.0M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
N/A
7.49%
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
$230,981,000.00
$1,003,982,000.00
Revenue This Year
$1,115.92
$2.29
Revenue Next Year
$81.04
$2.04
P/E Ratio
N/A
$112.89
Revenue Growth
N/A
1.77
52 Week Low
$1.23
$9.04
52 Week High
$5.47
$16.94

Technical Indicators

Market Signals
Indicator
PGEN
DEI
Relative Strength Index (RSI) 50.55 63.31
Support Level $3.49 $9.17
Resistance Level $4.44 $10.59
Average True Range (ATR) 0.31 0.31
MACD 0.02 0.13
Stochastic Oscillator 57.83 90.44

Price Performance

Historical Comparison
PGEN
DEI

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.

Share on Social Networks: